Abstract
Retrospective review of a large national U.S. database (IBM MarketScan) from January 2007 to December 2016. Of 7906 patients who underwent carotid artery stenting (CAS), those receiving dual antiplatelet therapy including aspirin (ASA) and clopidogrel (Plavix) for <6 months had a higher stroke rate. However, they also had a significantly higher incidence of extracranial hemorrhage and a trend (P = .056) toward increased intracranial hemorrhage. Increased duration of post-CAS dual antiplatelet therapy is associated with lower rates of readmission for stroke but increased risk of extracranial and possibly intracranial hemorrhage. The potential benefit of prolonged dual antiplatelet therapy with regard to ischemic complications must be balanced with increased risk of extracranial hemorrhagic complications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
